TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Published version of a preprint
Abstract
Activating mutations in the EGFR gene are important targets in cancer therapy because they are key drivers of non–small cell lung cancer (NSCLC). Although almost all common EGFR mutations, such as exon 19 deletions and the L858R point mutation in exon 21, are sensitive to EGFR-tyrosine kinase inhibitor (TKI) therapies, NSCLC driven by EGFR exon 20 insertion mutations is associated with poor clinical outcomes due to dose-limiting toxicity, demonstrating the need for a novel therapy. TAS6417 is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. In cell viability assays using Ba/F3 cells engineered to express human EGFR, TAS6417 inhibited EGFR with various exon 20 insertion mutations more potently than it inhibited the WT. Western blot analysis revealed that TAS6417 inhibited EGFR phosphorylation and downstream molecules in NSCLC cell lines expressing EGFR exon 20 insertions, resulting in caspase activation. These characteristics led to marked tumor regression in vivo in both a genetically engineered model and in a patient-derived xenograft model. Furthermore, TAS6417 provided a survival benefit with good tolerability in a lung orthotopic implantation mouse model. These findings support the clinical evaluation of TAS6417 as an efficacious drug candidate for patients with NSCLC harboring EGFR exon 20 insertion mutations. Mol Cancer Ther; 17(8); 1648–58. ©2018 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TAS6417 demonstrated in vitro and in vivo activity against a diverse range of exon 20 insertions, including A763_Y764insFQEA, D770_N771insG, and H773_V774insPH.
“TAS6417 is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type EGFR, which recently demonstrated in vitro and in vivo activity against a diverse range of exon 20 insertions, including A763_Y764insFQEA, D770_N771insG, and H773_V774insPH [79].”
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
Caspases: the executioners of apoptosis
Cohen, G. M. (1997) · Biochemical Journal · doi:10.1042/bj3260001 · Cited by 4,720 · see citing works
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377 · see citing works
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · see citing works
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978 · see citing works
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002 · see citing works
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1970 · Cited by 792 · see citing works
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677 · see citing works
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610 · see citing works
Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · see citing works
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484 · see citing works
Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473 · see citing works
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360 · see citing works
Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324 · see citing works
Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319 · see citing works
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283 · see citing works
Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234 · see citing works
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211 · see citing works
Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203 · see citing works
Redox Regulation of Epidermal Growth Factor Receptor Signaling through Cysteine Oxidation
Truong, T. H., & Carroll, K. S. (2012) · Biochemistry · doi:10.1021/bi301441e · Cited by 198 · see citing works
Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., Chou, T.-Y., Enriquez, M. L. D., Lee, G. K., Iqbal, J., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000422 · Cited by 182 · see citing works
Péus, D., Hamacher, K. L., & Pittelkow, M. R. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12340759 · Cited by 167 · see citing works
Hirano, T., Yasuda, H., Tani, T., Hamamoto, J., Oashi, A., Ishioka, K., Arai, D., Nukaga, S., Miyawaki, M., Kawada, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5887 · Cited by 165 · see citing works
EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL
Stoll, S. W., Benedict, M., Mitra, R. S., Hiniker, A. O., Elder, J. T., & Núñez, G. (1998) · Oncogene · doi:10.1038/sj.onc.1201657 · Cited by 113 · see citing works
Costa, D. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.04 · Cited by 71 · see citing works
Yang, M., Xu, X., Cai, J., Ning, J., Wery, J. P., & Li, Q. (2016) · International Journal of Cancer · doi:10.1002/ijc.30047 · Cited by 55 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Harrison, P. T., Vyse, S., & Huang, P. H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.015 · Cited by 625 · see citing works
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 454 · see citing works
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 380 · see citing works
Dong, R., Zhu, M., Liu, M., Xu, Y., Yuan, L.-L., Bian, J., Xia, Y., & Kong, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105583 · Cited by 206 · see citing works
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 203 · see citing works
Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 195 · see citing works
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 171 · see citing works
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 127 · see citing works
Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., Xia, B., Zhu, V. W., Nagasaka, M., Yang, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.014 · Cited by 113 · see citing works
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works
Meador, C. B., Sequist, L. V. D., & Piotrowska, Z. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0226 · Cited by 104 · see citing works
Tyrosine Kinase Receptors in Oncology
Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 100 · see citing works
Masood, A., Kancha, R. K., & Subramanian, J. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.004 · Cited by 83 · see citing works
Udagawa, H., Hasako, S., Ohashi, A., Fujioka, R., Hakozaki, Y., Shibuya, M., Abe, N., Komori, T., Haruma, T., Terasaka, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0419 · Cited by 75 · see citing works
Self-citationQin, Y., Jian, H., Tong, X., Wu, X., Wang, F., Shao, Y. W., & Zhao, X. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12710 · Cited by 66 · see citing works
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 66 · see citing works
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Li, S., Correia, G. S. D. C., Wang, J., Manochakian, R., Zhao, Y., & Lou, Y. (2023) · Cancers · doi:10.3390/cancers15112899 · Cited by 62 · see citing works
Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 62 · see citing works
Piotrowska, Z., Tan, D. S. W., Smit, E. F., Spira, A. I., Soo, R. A., Nguyen, D., Lee, V. H.-F., Yang, J. C., Velcheti, V., Wrangle, J. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00152 · Cited by 61 · see citing works
Wu, J., Yu, C., & Shih, J. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.018 · Cited by 58 · see citing works
Hasegawa, H., Yasuda, H., Hamamoto, J., Masuzawa, K., Tani, T., Nukaga, S., Hirano, T., Kobayashi, K., Manabe, T., Terai, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.039 · Cited by 50 · see citing works
Ikemura, S., Yasuda, H., Matsumoto, S., Kamada, M., Hamamoto, J., Masuzawa, K., Kobayashi, K., Manabe, T., Arai, D., Nakachi, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819430116 · Cited by 49 · see citing works
Hongo, T., Yamamoto, H., Jiromaru, R., Nozaki, Y., Yasumatsu, R., Hashimoto, K., Yoneda, R., Sugii, A., Taguchi, K., Masuda, M., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001566 · Cited by 43 · see citing works
Zhao, Y., Wang, H., & He, C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03828-8 · Cited by 43 · see citing works
EGFR exon 20 insertion mutations in non-small cell lung cancer
Wang, F., Li, C., Wu, Q., & Lu, H. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.10 · Cited by 40 · see citing works
Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37 · see citing works
He, Q., Qu, M., Bao, H., Xu, Y., Shen, T., Tan, D., Barkat, M. Q., Xu, C., Zeng, L., & Wu, X. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.003 · Cited by 37 · see citing works
Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 38 · see citing works
Upadhya, A., Yadav, K. S., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825377 · Cited by 37 · see citing works
Haele, M. V., Borght, S. V., Ceulemans, A., Wieërs, M. L. A. J., Metsu, S., Sagaert, X., & Weynand, B. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205970 · Cited by 36 · see citing works
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34 · see citing works
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Vyse, S., & Huang, P. H. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2016397 · Cited by 31 · see citing works
Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
Seo, D., & Lim, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115917 · Cited by 28 · see citing works
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Gao, Y., Vallentgoed, W., & French, P. J. (2018) · Cancers · doi:10.3390/cancers10120489 · Cited by 27 · see citing works
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
Low, J. L., Lim, S. M., Lee, J. B., Cho, B. C., & Soo, R. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146131 · Cited by 25 · see citing works
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 26 · see citing works
EGFR-mutant NSCLC: emerging novel drugs
Ye, L., Chen, X., & Zhou, F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000701 · Cited by 22 · see citing works
Malik, V., Kumar, V., Kaul, S. C., Wadhwa, R., & Sundar, D. (2021) · Biomolecules · doi:10.3390/biom11020160 · Cited by 21 · see citing works
Self-citationPiotrowska, Z., Passaro, A., Nguyen, D., Ruiter, G., Soo, R. A., Lee, V. H.-F., Velcheti, V., Tan, D. S. W., Lee, S., Kim, S. H., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00763 · Cited by 20 · see citing works
Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 20 · see citing works
Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors
Shaikh, G. M., Murahari, M., Thakur, S., Kumar, M. S., & Mayur, Y. C. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.108114 · Cited by 19 · see citing works
New therapeutic approaches to overcoming resistant EGFR exon 20 alterations
Li, A. M., Boichard, A., Felip, E., & Kurzrock, R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102990 · Cited by 19 · see citing works
Popović, L., Wintgens, J. P., Wu, Y., Brankatschk, B., Menninger, S., Degenhart, C., Jensen, N., Wichert, S. P., Klebl, B., Rossner, M. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108839 · Cited by 17 · see citing works
Hu, M., Zhong, C., Wang, J., Chen, J., & Zhou, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399975 · Cited by 17 · see citing works
Belloni, A., Pugnaloni, A., Rippo, M. R., Valerio, S. D., Giordani, C., Procopio, A. D., & Bronte, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104246 · Cited by 15 · see citing works
Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
Chen, H., Hu, S., Patterson, A. V., Smaill, J. B., Ding, K., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00875 · Cited by 14 · see citing works
Shi, C., Xing, R., Li, M., Feng, J., Sun, R., Wei, B., Guo, Y., Ma, J., & Wang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949304 · Cited by 15 · see citing works
Heymach, J. V., Yu, H. A., Besse, B., Cheng, Y., Tan, D. S. W., Li, W., Wacheck, V., & Nishio, M. (2025) · Future Oncology · doi:10.1080/14796694.2025.2457294 · Cited by 13 · see citing works
TAS2940 , a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations
Oguchi, K., Araki, H., Tsuji, S., Nakamura, M., Miura, A., Funabashi, K., Osada, A., Tanaka, S., Suzuki, T., Kobayashi, S. S., et al. (2022) · Cancer Science · doi:10.1111/cas.15617 · Cited by 12 · see citing works
de Wit, M., Gao, Y., Mercieca, D., de Heer, I. J., Valkenburg, B., van Royen, M. E., Aerts, J. G. J. V., Smitt, P. A. E. S., & French, P. J. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102796 · Cited by 13 · see citing works
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
Malapelle, U., Pilotto, S., Reale, M. L., Passiglia, F., Pisapia, P., Pepe, F., Belluomini, L., Galetta, D., Cortinovis, D. L., Tiseo, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103536 · Cited by 13 · see citing works
Kagawa, Y., Hayashida, T., Liu, J., Mori, S., Izumi, H., Kumagai, S., Udagawa, H., Hattori, N., Goto, K., & Kobayashi, S. S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100462 · Cited by 12 · see citing works
Okahisa, M., Udagawa, H., Matsumoto, S., Kato, T., Yokouchi, H., Furuya, N., Kanemaru, R., Toyozawa, R., Nishiyama, A., Ohashi, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107798 · Cited by 11 · see citing works
Gao, X., Wei, X., Zheng, M.-Y., Chen, Z.-H., Zhang, X., Zhong, W., Yang, J., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1630 · Cited by 11 · see citing works
Ueno, H., Hoshino, T., Yano, W., Tsukioka, S., Suzuki, T., Hara, S., Ogino, Y., Chong, K. T., Suzuki, T., Tsuji, S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03516-4 · Cited by 10 · see citing works
Self-citationPan, B., Liang, J., Shi, H., Rao, K., Guo, W., & Zhan, C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15127 · Cited by 9 · see citing works
Kunimasa, K., Nishino, K., Kukita, Y., Matsumoto, S., Kawachi, H., Kawamura, T., Inoue, T., Tamiya, M., Honma, K., Sugimoto, N., et al. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.04.001 · Cited by 10 · see citing works
Xie, C., Kong, J., Miao, F., Wang, X., & Sheng, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13487 · Cited by 9 · see citing works
Milgram, B. C., Borrelli, D. R., Brooijmans, N., Henderson, J. A., Hilbert, B. J., Huff, M. R., Ito, T., Jackson, E. L., Jonsson, P., Ladd, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02377 · Cited by 8 · see citing works
Pagliarini, R. A., Henderson, J. A., Milgram, B. C., Borrelli, D. R., Brooijmans, N., Hilbert, B. J., Huff, M. R., Ito, T., Kryukov, G. V., Ladd, B., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3833 · Cited by 10 · see citing works
Zhao, H., Beyett, T. S., Jiang, J., Rana, J. K., Schaeffner, I. K., Santana, J., Janne, P. A., & Eck, M. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417144121 · Cited by 8 · see citing works
Man, X., Sun, X., Chen, C., Xiang, Y., Zhang, J., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1367204 · Cited by 7 · see citing works
Liu, H., Qin, J., & Qian, X. (2024) · Cancer Control · doi:10.1177/10732748241292782 · Cited by 7 · see citing works
Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations
Sangwan, K., & Agarwal, G. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01588-7 · Cited by 6 · see citing works
An overview of recent advancements in targeted cancer therapies and their potential clinical impact
Ahmed, S., Sakla, A. P., Jahan, K., Neshat, N., Akhter, M., Aaghaz, S., & Kamal, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00740b · Cited by 6 · see citing works
Zhu, W., Pei, J., & Lu, X. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446220 · Cited by 6 · see citing works
Shen, C., Ho, H., Yeh, Y., Chiu, C., & Chou, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000277 · Cited by 6 · see citing works
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 5 · see citing works
Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7 · see citing works
Lu, H.-L., Jie, G., & Wu, Y.-L. L. C. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2063836 · Cited by 6 · see citing works
Liu, J., Xiang, Y., Fang, T., Zeng, L., Sun, A., Lin, Y., & Lu, K. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.11.010 · Cited by 5 · see citing works
Yu, L., Wang, R., Zhao, Y., Wu, Y., Wang, L., Chen, H., He, Z., Wang, Q., & Wu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231168466 · Cited by 4 · see citing works
TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations
Kasuga, H., Kataoka, Y., Yamamoto, F., Miyamoto, R., Tsuji, S., Suzuki, T., & Mizuarai, S. (2026) · Communications Medicine · doi:10.1038/s43856-026-01546-1 · Cited by 3 · see citing works
Animal models and in vivo investigations for drug repurposing in lung cancer
Chang, H.-W. K., & Chang, V. H. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00010-5 · Cited by 2 · see citing works
EGFR exon 20 insertion in non-small cell lung cancer
Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2 · see citing works
Chen, X., Huang, Y., Xu, W., Cai, Y., & Yang, Y. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00139j · Cited by 2 · see citing works
Chen, Y., Liu, Q.-P., Yang, S.-J., Ding, J., Lu, X.-Y., & Xie, H. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01855-0 · Cited by 1 · see citing works
de Wit, M., Gao, Y., Mercieca, D., de Heer, I. J., Valkenburg, B., van Royen, M. E., Aerts, J. G. J. V., Smitt, P. A. E. S., & French, P. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/798314
[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou, W., Zhang, W., & Han, B. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.07
Jiang, J., Zheng, P., & Li, L. (2023) · The Journal of Membrane Biology · doi:10.1007/s00232-023-00300-1
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023
Lin, D. W., Armstrong, M., Jiang, J. B., del Pozo, J., & Teijaro, C. N. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch18
Swaih, A. M., Talbot, S., Savoca, A., Thorpe, H., Flemington, V., Phillips, B., Colclough, N., McCoull, W., Radeva, V., Hargreaves, D., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102305 · Cited by 1 · see citing works
Determination of Zipalertinib Using LC‐ESI‐MS/MS and Application to Pharmacokinetic Study in Mice
Dixit, A., & Das, A. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70228
Wang, C., Cen, Y., Zhang, M., Tang, J., Yan, Z., Xie, L., Sun, D., Zhou, W., Wang, J., Yu, P., et al. (2026) · The Innovation · doi:10.1016/j.xinn.2026.101313
Advances in Targeted Therapy for EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer
苗, 贤. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641492
The Co-occurrence of EGFR Mutation and 16s rRNA in the Genome of Lung Cancer Patients
Sett, S., Dan, S., Alam, P., Dhara, P., Bera, R., Dey, S., De, T., Chakrabarti, J., Sengupta, S., Mandal, S., et al. (2026) · Journal of Current Oncological Trends · doi:10.4103/jcot.jcot_2_26
Jo, S., Jang, H., Kim, S., & Jang, J. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2730846
BindingDB (2024) · UC San Diego · doi:10.7270/q2cv4p5p
- Authors
- Hasako, S., Terasaka, M., Abe, N., Uno, T., Ohsawa, H., Hashimoto, A., Fujita, R., Tanaka, K., Okayama, T., Wadhwa, R., Miyadera, K., Aoyagi, Y., Yonekura, K., & Matsuo, K.
- Affiliations
- Taiho Pharmaceutical (Japan) (JP)
- National Institute of Advanced Industrial Science and Technology (JP)
- Venue
- Molecular Cancer Therapeutics
- Published
- 2018-07-31
- Volume
- 17
- Issue
- 8
- Pages
- 1648-1658
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2799325482
- Cited by
- 88
- References
- 36
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 10 · 2023: 13 · 2022: 9 · 2021: 12 · 2020: 18 · 2019: 10 · 2018: 2
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR exon 20 insertion, EGFR tyrosine kinase inhibitors, non-small cell lung cancer, EGFR phosphorylation, caspase activation, patient-derived xenografts, genetically engineered mouse models, drug tolerability, targeted cancer therapy
- MeSH terms
- Animals, Disease Models, Animal, Exons, Female, Humans, Male, Mutation, Protein Kinase Inhibitors, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
